Drugs / 15.GPC3-CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06815432 | Oct 2025 → Dec 2029 expected | brain glioblastoma | Baylor College of Medicine | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 15.GPC3-CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06815432 ↗ |
| Known as | GO-CART T cells | “This study will test T cells with the IL15 GPC3-CAR (GO-CART T cells) in participants with GPC3-positive brain tumors.” NCT06815432 ↗ |
| Action | Deplete | “we can put a new gene (a tiny part of what makes-up DNA and carries the participants traits) into T cells that will make them recognize cancer cells and kill them.” NCT06815432 ↗ |
| Modality | Cell therapy | “This study will test T cells genetically engineered with a GPC3-CAR and IL15 (GO-CART T cells) in participants with GPC3-positive brain tumors.” NCT06815432 ↗ |
| Route | Other | “the cells will then be thawed and administered in the participants tumor area, called an intracavitary administration” NCT06815432 ↗ |
| Target | GPC3 | “This study will test T cells genetically engineered with a GPC3-CAR and IL15 (GO-CART T cells) in participants with GPC3-positive brain tumors.” NCT06815432 ↗ |